Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2007-02-06
2007-02-06
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009100, C424S130100, C424S139100, C435S008000, C536S022100, C536S023100, C536S023400
Reexamination Certificate
active
10252131
ABSTRACT:
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 239400 (1994-08-01), None
Seder and Gros, 1995, “The functional role of CD8+T helper type 2 cells”, J Exp Med 181:5-7.
Bergers et al., 1994, “Alternative promoter usage of the Fos-responsive geneFit-1generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor”, EMBO J 13(5):1176-1188.
Gavett et al., 1994, “Depletion of murine CD4+T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia”, Am J Respir Cell Mol Biol 10:587-593.
Kaneshima et al., 1994, “Human hematolymphoid cells in SCID mice”, Curr Opin Immunol 6:327-333.
Lukacs et al., 1994, “Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma”, Am J Respir Cell Mol Biol 10:526-532.
Maggi et al., 1994, “Th2-like CD8+T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection”, J Exp Med 180:489-495.
Maggi et al., 1994, “Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 to TH0 cells”, Science 265:244-248.
Manetti et al., 1994, “CD30 expression by CD8+T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+T cell clones in human immunodeficiency virus infection”, J Exp Med 180:2407-2411.
Marsh et al., 1994, “Linkage analysis ofIL4and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations”, Science 264:1152-1156.
Chen et al., 1993, “RAG-2-deficient blastocyst complementation: An assay of gene function in lymphocyte development” Proc Natl Acad Sci USA 90:4528-4532.
Clerici et al., 1993, “Restortation of HIV-specific cell-mediated immune responses by interleukin-12 in vitro”, Science 262:1721-1724.
Clerici et al., 1993, “Changes in interleukin-2 and interleukin-4 production in asymptomatic-human immunodeficiency virus-seropositive individuals”, J Clin Invest 91:759-765.
Kanagawa et al., 1993, “Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS)”, Science 262:240-242.
Robinson et al., 1993, “Activation of CD4+T cells, increased TH2-type cytokine mRNA expression, eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma”, J Allergy Clin Immunol 92:313-324.
Yanagisawa et al., 1993, “Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1”, FEBS Lett 318(1):83-87.
Liang and Pardee, 1992, “Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction”, Science 257:967-971.
Shinkai et al., 1992, “RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement”, Cell 68:855-867.
Tominaga et al., 1992, “Nucleotide sequence of a complementary DNA for human ST2”, Biochim Biophys Acta 1171:215-218.
Werenskiold, 1992, “Characterization of a secreted glycoprotein of the immunoglobulin superfamily inducible by mitogen and oncogene”, Eur J Biochem 204:1041-1047.
Young et al., 1992, “Expression of cytolytic mediators by synovial fluid lymphocytes in rheumatoid arthritis”, Am J Path 140(5):1261-1268.
Del Prete et al., 1991 , “Purified protein derivative ofmycobacterium tuberculosisand excretory-secreted antigen(s) ofToxocara canisexpand in vitro human T cells with stable and opposite (Type 1 T helper or Type 2 T helper) profile f cytokine production”, J Clin Invest 88:346-350.
Ebnet et al., 1991, “In vivoprimed mouse T cells selectively express T cell-specific serine proteinase-1 and the proteinase-like molecules granzyme B and C”, Int Immunol 3(1):9-19.
McMahan et al., 1991, “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types”, EMBO J 10(10):2821-2832.
Moll et al., 1991, “Expression of T-cell-associated serine proteinase 1 during murineLeishmania majorinfection correlates with susceptibility to disease”, Infect Immun 59(12):4701-4705.
Mosmann and Moore, 1991, “The role of IL-10 in crossregulatin of TH1 and TH2 responses”, Immunol Today 12:A49-A53.
Tominaga et al., 1991, “Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping”, Biochim Biophys Acta 1090:1-8.
Yamamura et al., 1991, “Defining protective responses to pathogens: Cytokine profiles in leprosy lesins”, Science 254:277-279.
Makino et al., 1990, “H-2-associatd and background genes influence the development of a murine retrovirus-induced immunodeficiency syndrome”, J Immunol 144(11):4347-4355.
Murphy et al., 1990, “Induction by antigen of intrathymic apoptosis od CD4+CD8+TCRlothymocytes in vivo”, Science 250:1720-1723.
Ojcius and Young, 1990, “Cell-mediated killing: Effector mechanisms and mediators”, Cancer Cells 2:138-145.
Wiernenga et al., 1990, “Evidence for compartmentalizatin of functional subsets of CD4+T lymphocytes in atopic patients”, J Immunol 144(12):4651-4656.
Cooper et al., 1989, “Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridizatin”, J Exp Med 169:1565-1581.
Firestein et al., 1989, “A new murine CD4+T cell subset with an unrestricted cytokine profile”, J Immunol 143(2):518-525.
Klemenz et al., 1989, “Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen”, Proc Natl Acad Sci USA 86:5708-5712.
Liu et al., 1989, “Perforin and serine esterase gene expression in stimulted human T cells”, J Exp Med 170:2105-2118.
Mosmann and Coffman, 1989, “TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties”, Ann Rev Immunol 7:145-173.
Tominaga, 1989, “A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin1 receptor”, FEBS Lett 258(2):301-304.
Werenskiold et al., 1989, “Induction of a mitogen-responsive gene after expression of the Ha-rasoncogene in NIH 3T3 fibroblasts”, Mol Cell Biol 9(11):5207-5214.
Fruth et al., 1988, “Determination of frequency of T cells expressing the T cell-specific serine proteinase 1 (TSP-1) reveals two types of L3T4+T lymphocytes”, Eur J Immunol 18:773-781.
Mueller et al., 1988, “A high proportion of T lymphocytes that infiltrate H-2-incompatible heart allograft
Jones Day
Millennium Pharmaceuticals Inc.
Swartz Rodney P
LandOfFree
Compositions and methods for the treatment and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834394